BioNTech and Bristol Myers report encouraging Phase 2 data for Pumitamig in advanced NSCLC

BioNTech and Bristol Myers Squibb released initial findings from the global Phase 2 ROSETTA Lung-107 trial (NCT06841055) evaluating bispecific PD-L1xVEGF-A candidate Pumitamig (BNT327/BMS986545) in combination with docetaxel, reporting an objective response rate of 36.7%.

Detected & updated continuously · Source: Nebula